2019
MaxCyte to Present Updates on ExPERT™ Platform at Upcoming Conferences
MaxCyte Presents Updates on First-in-class CARMA™ Platform at Upcoming Meetings
MaxCyte Announces Presentation at ICLE 2019
MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform
MaxCyte CEO Doug Doerfler to Present at 2019 BIO International Convention
MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform
MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing
MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies
New Processing Assemblies Deliver Increased Flexibility, Efficiency, and Ease of Cell Recovery
NK Cells: The Latest Recruits in the Battle Against Cancer
Don’t Settle for Just Your Average CHO and Other Cell Line Development Advances
MaxCyte to Present on CARMA™ Platform at Two Upcoming Industry Conferences in Europe
MaxCyte CEO Doug Doerfler to Present at ARM’s 7th Annual Cell & Gene Therapy Investor Day
MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company
MaxCyte: Driving New Generation of Cell-Based Medicines
Hitachi Chemical Advanced Therapeutics Solutions Completes Technology Transfer to Enable Manufacturing of MaxCyte’s CARMA™ Cell Therapy for Clinical Use
2018
MaxCyte to Present on Its CARMA™ Platform During Biotech Showcase™and Phacilitate: Leaders World/World Stem Cell Summit 2019
MaxCyte to Present at Piper Jaffray 30th Annual Healthcare Conference
Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
MaxCyte to Present on CARMA™ Platform at BIO-EUROPE®
MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors
MaxCyte, Inc. to Present on CARMA™ Platform at Two Upcoming Industry Conferences
MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program
MaxCyte and U.S. National Institutes of Health’s National Heart, Lung, and Blood Institute Enter Cooperative Research & Development Agreement for Sickle Cell Disease
MaxCyte, Inc. to Present at 2018 BIO International Convention
MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Efficient Correction of Sickle Cell Mutation in Hematopoietic Stem Cells (HSC)
MaxCyte Appoints Dr.Claudio Dansky Ullmann as Chief Medical Officer
MaxCyte, Inc. to Present at BIO Europe and BIOCapital USA Conferences this Month
Dr. Richard Douglas Joins MaxCyte Board
MaxCyte, Inc. to Present at Two Life Sciences Conferences
2017
MaxCyte, Inc. to Present at Phacilitate’s Cell & Gene Therapy Europe Conference
MaxCyte Appoints Executive Vice President of Global Marketing
MaxCyte and National Institute of Allergy and Infectious Diseases to Collaborate on Research for Ultra-Rare Disease Therapy
MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell Disease
CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement with Maxcyte
MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting
MaxCyte, Inc. to Present at Phacilitate Cell & Gene Therapy World Conference
MaxCyte, NIH NIAID Study Published in Science Translational Medicine Demonstrates CRISPR-Cas9 Repair of X-linked Chronic Granulomatous Disease (CGD) Gene
MaxCyte, Inc. to Present Pre-Clinical Data for Targeted Gene-Correction in a Rare Disease at Keystone Symposia on Precision Genome Engineering
2016
MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies
MaxCyte Appoints Executive Vice President, Business and Strategic Development
MaxCyte, Inc. to Present at 2016 Cell & Gene Meeting on the Mesa and Biotech Week Boston 2016
MaxCyte Bolsters Distributor Network in Asia to Meet Growing Market Demands for MaxCyte STX® and MaxCyte VLX® Transfection Systems
MaxCyte Announces a CRADA with US Army Medical Research Institute of Infectious Diseases for an Exploratory Research Collaboration on Rapid Response Medical Countermeasures
MaxCyte to Present Gene Editing Results at the American Society of Gene and Cell Therapy Annual Meeting
MaxCyte Partner to Present Data at the Inaugural Bioprocess International West Conference
MaxCyte to Present Data on Expression and Functionality of Bispecific Antibodies Produced via Transient Transfection
MaxCyte Partners to Present Data at Annual Biophysical Society Meeting
MaxCyte, Inc. to Present at Biotech Showcase 2016
2015
MaxCyte Appoints Spinco Biotech Pvt Ltd. as Distributor in India for the MaxCyte STX® and MaxCyte VLX®
MaxCyte to present novel approach to CAR-T for treatment of solid tumors at Biochemical Society in London
MaxCyte, Inc. to Present at 2015 Immuno-Oncology Conference
MaxCyte to Present New Data on Expression and Functionality of Bispecific Antibodies Produced via Transient Transfection
MaxCyte Appoints Chayon Laboratories as Distributor in Korea for the MaxCyte STX® and MaxCyte VLX®
MaxCyte to Present Data on the Ability of Flow Electroporation to Streamline Antibody Development and Production
MaxCyte Awarded Maryland Stem Cell Research Fund Grant
MaxCyte to Present Data on Development of ‘Enhanced’ Potency Cell Therapy Products
MaxCyte and Partners to Present Data at American Society of Gene and Cell Therapy Meeting
MaxCyte to Present Data on Achieving 2.7 grams/Liter of Antibody in CHO Cells With Flow Electroporation
MaxCyte Appoints Cold Spring Biotech Corp. as Distributor in China, Taiwan, and Hong Kong for the MaxCyte STX® and MaxCyte VLX®
MaxCyte and The Johns Hopkins Kimmel Cancer Center Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies
MaxCyte to Present at the 2015 Jefferies Immuno-Oncology Summit
MaxCyte Publishes Data on Gram/Liter Antibody Production in the Journal of Biomolecular Screening
MaxCyte to Present at 3rd Annual Regen Med Investor Day
MaxCyte to Present Data Demonstrating the Impact of Flow Transfection on Improving Protein Expression
2014
MaxCyte Appoints Executive Vice President of Global Sales
Accelerating Product Development: From Transient Transfection to Stable Pools and Stable Clones
MaxCyte Introduces Rapid, Automated, Scalable Flow Electroporation-based Technology for Vaccine Development
MaxCyte Introduces the 2014 MaxCyte STX® Scalable Transfection System at CHI’s 13th Annual PepTalk Conference in Palm Springs, Booth #308
